← Back to Search

Drug-Checking Services + PrEP for HIV Prevention (SCOPE Trial)

N/A

Recruiting

Led By Susan Sherman, PhD

Research Sponsored by Johns Hopkins Bloomberg School of Public Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured at 6, 12, 18 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will provide drug-checking services and PrEP to people who use drugs in Baltimore to reduce overdose and HIV.

Who is the study for?

This trial is for adults over 18 in Baltimore who use stimulants or opioids, have had unprotected sex recently, are HIV negative, and may have had an STI. They must be willing to undergo drug screening, HIV and STI testing. Those too impaired or unable to consent can't join.

What is being tested?

The SCOPE study is evaluating a program that combines drug-checking services with PrEP (a medication preventing HIV) for people using drugs. The goal is to reduce both overdoses and new HIV infections among participants.

What are the potential side effects?

While the description doesn't list specific side effects, PrEP can sometimes cause nausea, headaches, stomach pain, weight loss and fatigue. Drug-checking services themselves do not involve taking medications but rather assessing substances' safety.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured at 6, 12, 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured at 6, 12, 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at 6, 12, 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in PrEP uptake as assessed by study team instrument items

Current PrEP status as assessed by study team instrument items

Secondary study objectives

Change in HIV Risk Behaviors as assessed by study team instrument items

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: SCOPE CohortExperimental Treatment1 Intervention

A cohort of PWUD (N=500) living in Baltimore. We will follow-up with participants every 6 months (for 18 months) in five recruitment zones throughout Baltimore (n=125/zone). The four recruitment zones will overlap the intervention sites. There will be four study visits (baseline, 6 months, 12 months, 18 months) total for participants.

Do I qualify?Apply below to find out